title: Perils of the Pathologic Complete Response.
authors.affiliation: Brent S. Rose, Harvard Radiation Oncology Program, Boston, MA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Brent S
authors.initials: BS
authors.lastname: Rose
authors.affiliation: Brent S. Rose, Harvard Radiation Oncology Program, Boston, MA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
authors.affiliation: Brent S. Rose, Harvard Radiation Oncology Program, Boston, MA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Harvey J
authors.initials: HJ
authors.lastname: Mamon
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods*; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D006801:Humans; D009369:Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D012107:Research Design; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome